Product Sales

9 Months Ended

Sep. 30, 2021

Revenue from Contract with Customer [Abstract]

Product Sales

Product Sales

Net product sales consist of the following:

(In millions)	Three Months Ended September 30,					Nine Months Ended September 30,
Net Product Sales in the United States	2021			2020		2021			2020
EYLEA®	$	1,473.4		$	1,318.3	$	4,245.1		$	3,604.0
Libtayo®	78.4			71.6		225.5			196.6
Praluent®	44.8			48.5		130.0			95.7		*
REGEN-COV®	676.7			40.2		3,530.1			40.2
Evkeeza®	6.6			—		9.1			—
ARCALYST®	—		**	3.6		2.2		**	9.3
	$	2,279.9		$	1,482.2	$	8,142.0		$	3,945.8
* Effective April 1, 2020, the Company became solely responsible for the development and commercialization of Praluent in the United States and records net product sales of Praluent in the United States. Previously, Sanofi recorded net product sales of Praluent in the United States. See Note 3 for further details.
** Effective April 1, 2021, Kiniksa records net product sales of ARCALYST in the United States. Previously, the Company recorded net product sales of ARCALYST in the United States.

As of September 30, 2021 and December 31, 2020, the Company had $4.086 billion and $3.112 billion, respectively, of trade accounts receivable that were recorded within Accounts receivable, net.

The Company had product sales to certain customers that accounted for more than 10% of total gross product revenue for the three and nine months ended September 30, 2021 and 2020. Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
Besse Medical, a subsidiary of AmerisourceBergen Corporation	40	%	50	%	33	%	52	%
McKesson Corporation	24	%	34	%	20	%	34	%
U.S. Government (see Note 3)	25	%	*		38	%	*
* Sales to the U.S. Government represented less than 10% of total gross product revenue during the period.